Health economic impact of liquid biopsies in cancer management

Maarten J. IJzerman*, A. M.Sofie Berghuis, Johann S. de Bono, Leon W.M.M. Terstappen

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)


Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.

Original languageEnglish
Pages (from-to)593-599
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number6
Publication statusPublished - 2 Nov 2018
Externally publishedYes


  • biomarker
  • cancer
  • circulating tumor cells
  • ctDNA
  • diagnostic
  • health economics
  • Liquid biopsies


Dive into the research topics of 'Health economic impact of liquid biopsies in cancer management'. Together they form a unique fingerprint.

Cite this